Catheter-directed thrombolysis prevents early collapse in intermediate-high-risk PE

Design

Multicentre, open-label randomised trial

Population

558 haemodynamically stable adults with intermediate-high-risk acute PE

Primary outcome

Death, recurrent PE or cardiorespiratory decompensation within 7 days

Effect

0.7% vs 6.8%; RR 0.10 (95% CI 0.02–0.44)

PRAGUE-26 randomised 558 patients with intermediate-high-risk pulmonary embolism — haemodynamically stable, but with right ventricular dysfunction and a raised troponin or natriuretic peptide — to catheter-directed alteplase plus anticoagulation or anticoagulation alone. Median age was 64.

The composite of death, recurrent PE or cardiorespiratory decompensation within 7 days occurred in 0.7% with thrombolysis and 6.8% with anticoagulation alone (RR 0.10, 95% CI 0.02–0.44). Most of the difference was decompensation or collapse. Clinically relevant bleeding (4.6% vs 5.0%) and major bleeding (1.4% vs 2.2%) did not differ significantly, but there were two intracranial haemorrhages with thrombolysis and none without. Four patients died within 7 days on anticoagulation alone; one died by 30 days with thrombolysis.

This is the first randomised evidence that catheter-directed lysis changes clinical outcomes rather than just right ventricular ratios. It was open-label, the event numbers are small, and the benefit rests on a composite driven by decompensation. It will shape PE response team decisions where the service exists.

• Risk-stratify every stable PE: look for right ventricular dilatation on CT or echo and check troponin or BNP.
• In intermediate-high-risk PE, discuss catheter-directed thrombolysis early with the PE team or interventional radiology.
• Expect about 6 fewer early decompensations per 100 treated patients, with a small intracranial haemorrhage risk.
• Monitor intermediate-high-risk patients closely in the first 72 hours even on anticoagulation alone.
• Catheter-directed therapy needs an interventional service; where none exists, plan escalation and transfer criteria in advance.

Why it matters

It turns intermediate-high-risk PE from watchful anticoagulation into a condition with an evidence-based escalation option.

Don't overread it

The benefit was driven by decompensation in an open-label trial; there is no mortality signal large enough to rely on.

The statistics, in plain English

A relative risk of 0.10 means events were about 90% less frequent with thrombolysis. The wide confidence interval (0.02–0.44) reflects small event numbers: 2 vs 19. The bleeding comparisons are not significant, but the trial was too small to rule out a meaningful rise in rare events such as intracranial haemorrhage.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.